Saturday, April 20, 2024
4/20/2024
PROJECT SUMMARY CD4+ T cells respond to peptide antigens presented by MHCII molecules (pMHCII) using a 5-module molecular machines composed of a receptor module [the T cell receptor (TCR)], three signaling modules (CD3¿¿, CD3¿¿, CD3¿¿), and a coreceptor module (CD4). Drawing upon this blueprint, we designed a biomimetic 5-module chimeric antigen receptor (5MCAR) system composed of a chimeric receptor module, built with pMHCII and TCR components (CRMpMHCII), that assembles with the CD3 signaling modules and works with a surrogate coreceptor (ScoR) to generate signals in response to specific TCRs. As we recently reported (Kobayashi, et al., PNAS 2020), 5MCAR-CTLs can specifically target and kill pathogenic CD4+ T cells that express TCRs that bind the CRMpMHCII. Given that peripheral T cell lymphomas (PTCLs) represent a unique type of pathogenic T cell for which treatment options are limited, and patient prognosis is poor, we are motivated to ask if our 5MCAR technology can be developed into a patient-specific PTCL therapy. As PTCLs are often derived from transformed CD4+ ¿¿T cells and express a clonotypic TCR that represents a tumor-specific antigen, we consider them to be ideal targets for 5MCAR-CTLs. Accordingly, the goal of the current study is to establish a workflow whereby our 5MCAR technology is used to screen libraries of CRMpMHCII for mimotope CRMpMHCII that signal in response to the clonotypic TCR of a PTCL, and then use the identified mimotope CRMpMHCII to generate 5MCAR-CTLs for targeting the PTCL via its clonotypic TCR. When completed, the established workflow will provide a blueprint for adapting our 5MCAR technology into a personalized therapy to treat patients with PTCLs.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
